For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard ...

Kiniksa will now focus its development efforts on the IL-1 blocker KPL-387, which it is testing for recurrent pericarditis ...

Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...

Adding obinutuzumab to standard therapy for active lupus nephritis led to significantly higher rates of complete renal ...

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...

Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025Anticipate completing enrollment in ...

Phase I Tiffany-01 trial is designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ADCE-T02 as a monotherapy in patients with advanced solid tumors COPENHAGEN, Denmark, Feb. 26 ...

On track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; BLA ...

ANDEMBRY® is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in HAE patients. The approval marks the fifth regulatory approval of ...

A Yale University study explores the newly defined post-vaccination syndrome (PVS), revealing alarming biological changes among affected individuals and potential paths for diagnosis and treatment.

Aplastic anaemia is a rare but serious blood disorder in which the bone marrow fails to produce enough blood cells—red blood cells, white blood cells, and platelets. This condition can lead to fatig ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission ...